4D Molecular Therapeutics Inc 2025年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedJune 30,2025OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THETRANSITION PERIOD FROMTOCommission File Number001-39782 4D Molecular Therapeutics, Inc. Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 4, 2025, there were46,702,467shares of 4D Molecular Therapeutics, Inc.’s common stock outstanding. This number does not include9,385,000shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of August 4, 2025 (which are immediatelyexercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations) sold in the registrant’s publicoffering in February 2024 or issued in exchange for our common stock in November 2024 and December 2024. Table of Contents FINANCIAL INFORMATION4Condensed Unaudited Financial Statements4Condensed Balance Sheets as of June 30, 2025 and December 31, 20244Condensed Statements of Operations for the Three and Six Months Ended June 30, 2025 and20245Condensed Statements of Comprehensive Loss for the Three and Six Months Ended June 30,2025 and 20246Condensed Statements of Stockholders’ Equity for the Three and Six Months Ended June 30,2025 and 20247Condensed Statements of Cash Flows for the Six Months Ended June 30, 2025 and 20249Notes to Unaudited Condensed Financial Statements10Management’s Discussion and Analysis of Financial Condition and Results of Operations31Quantitative and Qualitative Disclosures About Market Risk41Controls and Procedures41 PART II.OTHER INFORMATION Item 1.Item 1A.Item 2.Item 3.Item 4.Item 5.Item 6.Signatures Legal Proceedings43Risk Factors43Unregistered Sales of Equity Securities and Use of Proceeds111Default Upon Senior Securities111Mine Safety Disclosures111Other Information111Exhibits112113 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operationsand financial performance and condition, as well as our plans, objectives and expectations for our business operationsand financial performance and condition. Any statements contained herein that are not statements of historical factsmay be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements byterminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,”“expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,”“would” and other similar expressions that are predictions of or indicate future events and future trends, or the negativeof these terms or other comparable terminology. These forward-looking statements include, but are not limited to,statements about: •the success, cost and timing of our development activities, preclinical studies and clinical trials, including ourclinical trials for 4D-150, 4D-175, 4D-710, 4D-725 and 4D-310;•the number, size and design of our planned clinical trials, and what regulatory authorities may require toobtain marketing approval;•the timing of Investigational New Drug Application (“IND”) enabling studies and results from such studies;•the timing and success of lead optimization for our product candidates in lead optimization;•the translation of our preclinical results and data into future clinical trials in humans;•the timing of any manufacturing runs for materials to be us